Page last updated: 2024-11-06

inositol hexasulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Inositol hexasulfate (IHS) is a highly sulfated derivative of myo-inositol. Its synthesis is a complex process and has been achieved by various methods, often using strong sulfating agents. IHS has shown promising biological activities, including anti-inflammatory and anti-cancer effects, potentially due to its ability to modulate cell signaling pathways. Research on IHS is driven by its potential therapeutic applications, particularly in the treatment of inflammatory diseases and cancer. The unique structure and biological effects of IHS make it an interesting molecule for further investigation and development as a drug candidate.'

inositol hexasulfate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65302
CHEMBL ID3945401
SCHEMBL ID229321
SCHEMBL ID229322
SCHEMBL ID13399464
SCHEMBL ID15953861
SCHEMBL ID21067324
MeSH IDM0060525

Synonyms (24)

Synonym
IHS ,
d-myo-inositol-hexasulphate
myo-inositol hexasulfate
(2,3,4,5,6-pentasulfooxycyclohexyl) hydrogen sulfate
inositol hexasulfate
28434-25-5
DB01666
myoinositol hexasulfate
myo-inositol hexakis(hydrogen sulfate)
23330-83-8
inositol hexkissulfate
myo-inositol hexakissulfate
SCHEMBL229321
SCHEMBL229322
SCHEMBL13399464
SCHEMBL15953861
CHEMBL3945401 ,
bdbm50191320
(2,3,4,5,6-pentasulfooxycyclohexyl)hydrogen sulfate
(1r,2s,3r,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexakis(hydrogen sulfate)
Q27092850
SCHEMBL21067324
DTXSID50946000
cyclohexane-1,2,3,4,5,6-hexayl hexakis(hydrogen sulfate)

Research Excerpts

Overview

Myoinositol hexasulfate (IHS) is a powerful allosteric effector of oxygen binding by hemoglobin.

ExcerptReferenceRelevance
"Myoinositol hexasulfate (IHS) is a powerful allosteric effector of oxygen binding by hemoglobin. "( The allosteric effect of inositol hexasulfate on oxygen binding by hemoglobin.
Benesch, R; Benesch, RE; Edalji, R, 1976
)
1.18
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-adrenergic receptor kinase 1Bos taurus (cattle)IC50 (µMol)13.50000.03500.87371.3800AID1315719
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
desensitization of G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Bos taurus (cattle)
G protein-coupled receptor internalizationBeta-adrenergic receptor kinase 1Bos taurus (cattle)
negative regulation of the force of heart contraction by chemical signalBeta-adrenergic receptor kinase 1Bos taurus (cattle)
protein phosphorylationBeta-adrenergic receptor kinase 1Bos taurus (cattle)
intracellular protein transportBeta-adrenergic receptor kinase 1Bos taurus (cattle)
G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Bos taurus (cattle)
G protein-coupled acetylcholine receptor signaling pathwayBeta-adrenergic receptor kinase 1Bos taurus (cattle)
regulation of signal transductionBeta-adrenergic receptor kinase 1Bos taurus (cattle)
peptidyl-serine phosphorylationBeta-adrenergic receptor kinase 1Bos taurus (cattle)
positive regulation of smoothened signaling pathwayBeta-adrenergic receptor kinase 1Bos taurus (cattle)
negative regulation of striated muscle contractionBeta-adrenergic receptor kinase 1Bos taurus (cattle)
cardiac muscle contractionBeta-adrenergic receptor kinase 1Bos taurus (cattle)
negative regulation of relaxation of smooth muscleBeta-adrenergic receptor kinase 1Bos taurus (cattle)
positive regulation of protein localization to ciliumBeta-adrenergic receptor kinase 1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein kinase activityBeta-adrenergic receptor kinase 1Bos taurus (cattle)
G protein-coupled receptor kinase activityBeta-adrenergic receptor kinase 1Bos taurus (cattle)
protein bindingBeta-adrenergic receptor kinase 1Bos taurus (cattle)
ATP bindingBeta-adrenergic receptor kinase 1Bos taurus (cattle)
alpha-2A adrenergic receptor bindingBeta-adrenergic receptor kinase 1Bos taurus (cattle)
Edg-2 lysophosphatidic acid receptor bindingBeta-adrenergic receptor kinase 1Bos taurus (cattle)
beta-adrenergic receptor kinase activityBeta-adrenergic receptor kinase 1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmBeta-adrenergic receptor kinase 1Bos taurus (cattle)
cytosolBeta-adrenergic receptor kinase 1Bos taurus (cattle)
plasma membraneBeta-adrenergic receptor kinase 1Bos taurus (cattle)
membraneBeta-adrenergic receptor kinase 1Bos taurus (cattle)
cell projectionBeta-adrenergic receptor kinase 1Bos taurus (cattle)
presynapseBeta-adrenergic receptor kinase 1Bos taurus (cattle)
postsynapseBeta-adrenergic receptor kinase 1Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1315719Inhibition of bovine cerebral cortex GRK2 assessed as decrease in rhodopsin phosphorylation by SDS-PAGE analysis2016Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20
G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (37.14)18.7374
1990's9 (25.71)18.2507
2000's9 (25.71)29.6817
2010's4 (11.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.64 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]